January 7, 2020

Paris & Chicago Yseop, the world-leading AI software company and pioneer in Natural Language Generation (NLG), today announced a strategic partnership with Litera, a leading supplier of document drafting technology.

The Partnership brings together two complementary service offerings to empower Life Sciences companies with solutions for more efficient and effective management of regulatory compliance processes.

Bringing a new drug to market takes between 10 and 15 years and costs between $1.5 and $2.0 billion. In a context of heightened regulatory scrutiny and obligations, relying on manual reporting systems and complex, resource-intensive and time-consuming processes, can jeopardize the whole investment.

Litera is committed to accelerating the creation, review, formatting, and standardization of documents to offer the fastest path to compliance, with a dedicated offering for regulatory, medical affairs, and clinical operations specialists. Its solution portfolio (DocXtools for Life Sciences, Change-Pro Premier, and Content Companion) offers a best-of-breed combination to streamline and accelerate high-quality submissions.

Matt Miller, Litera Director of Product Management, comments: “Patients are waiting. This is the most important driving factor we bear in mind when working with Life Science companies. We are always looking for technologies that can help them complete submissions faster. Yseop’s expertise in AI-powered intelligent automation blends in well with our document processing technology and we are proud to be able to work collaboratively on offering the best approach to streamline regulatory submission.”

Working closely with some of the global leading pharmaceutical companies, Yseop has developed a specialized expertise in providing automated reporting solutions for medical writers, built on advanced artificial intelligence NLG technology. By automating some of the data-heavy, time-consuming manual reporting sections needed to ensure compliance and safety, Yseop’s NLG solution helps pharmaceutical companies save significant time and money and get drugs to market faster.

Emmanuel Walckenaer, CEO of Yseop, says: “NLG offers this unique ability to help scale human expertise and regulatory submission is one of the areas where the benefits it delivers proves the more valuable. We share with Litera the urge to provide Life Sciences company with the best technology available. We are delighted to enrich our respective ecosystem and are eager to have our joint clients combine our technologies and achieve new levels of regulatory compliance efficiency.”

Back to the Press page.